

# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Annemieke Aartsma-Rus

Organisation/Company: N/A

Country: Netherlands

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

#### 1.1 Employment

No interest declared

#### 1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Current	01-08-2020		PTC Therapeutics	Cross product related/ general (non product related)			Input on how to educate clinicians about genetics and genetic variants with lectures and social media
Current	01-08-2020		Splicesense	Cross product related/ general (non product related)			Oligonucleotide therapy development for cystic fibrosis
Past	01-02-2023	28-02-2023	Lilly	Cross product related/ general (non product related)			Options for genome editing therapy development for Duchenne muscular dystrophy
Current	01-01-2021		Galapagos	Cross product related/ general (non product related)			Therapeutic options for Duchenne muscular dystrophy
Current	01-01-2022		Entrada	Cross product related/ general (non product related)			Advise on preclinical development of exon skipping compounds for Duchenne muscular dystrophy
Current	01-01-2021		Regenxbio	Cross product related/ general (non product related)			Advise on preclinical studies and study results for AAV mediated delivery of antisense genes for exon skipping in Duchenne
Current	01-04-2022		Astra Zeneca	Cross product related/ general (non product related)			Oligonucleotide therapy for titin-related cardiomyopathy
Current	01-08-2020		Sarepta Therapeutics	Cross product related/ general (non product related)			Genetics and dystrophin

				related)			
Past	01-08-2020	01-12-2022	Alpha Anomeric	Cross product related/ general (non product related)			Advise on preclinical studies for alpha anomeric's chemical modification of oligonucleotides
Current	01-08-2020		Biomarin	Cross product related/ general (non product related)			Advise on preclinical development of exon skipping compounds for Duchenne muscular dystrophy
Current	01-01-2021		Takeda	Cross product related/ general (non product related)			Oligonucleotide therapies for Duchenne and myotonic dystrophy, gene editing therapy for Duchenne

### 1.3 Strategic advisory role

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Current	01-08-2020		Hybridize therapeutics	Cross product related/ general (non product related)			Oligonucleotide therapies for kidney diseases
Current	01-08-2020		Sarepta Therapeutics	Cross product related/ general (non product related)			Exon skipping therapy for Duchenne Gene therapy for neuromuscular disorders
Current	01-08-2020		Silence	Cross product related/ general (non product related)			Input on preclinical development of siRNA candidates and selection of target tissues for siRNA therapies

### 1.4 Financial interests

Name of pharmaceutical company	Financial interest	Other comments
LUMC	Intellectual Property Rights	LUMC has patents on exon skipping - i am a co-inventor on some of these patents and am entitled to a share of potential royalties

### 1.5 Principal investigator

No interest declared

### 1.6 Investigator

No interest declared

### 1.7 Grant / Funding to organisation /institution

Name of pharmaceutical company	Subject Matter
Sarepta Therapeutics	Unrestricted grant to identify muscle ho
Entrada Therapeutics	Unrestricted grant to perform natural hi

### 1.8 Close family member interest

No interest declared

### 1.9 Repurposing of a medicinal product

No interest declared

#### 1.10 Any other interests or facts

No interest declared

#### 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## 2.1 Employment

No interest declared

## 2.2 Consultancy

No interest declared

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

No interest declared

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name:	Annemieke Aartsma-Rus
------------	-----------------------

Date:	2023-08-10
-------	------------

For definitions of activities etc, refer to the policy on handling of competing interests.